6533b852fe1ef96bd12ab7f4

RESEARCH PRODUCT

“MIATA”—Minimal Information about T Cell Assays

Pedro RomeroSylvia JanetzkiCedrik M. BrittenHyam I. LevitskyHolden T. MaeckerMichael KalosAxel HoosLloyd J. OldMark M. DavisC. J. M. Melief

subject

T-LymphocytesT cellmedicine.medical_treatmentImmunologyHuman immunodeficiency virus (HIV)medicine.disease_causeT cell responseCancer VaccinesArticleMonitoring ImmunologicNeoplasmsmedicineHumansImmunology and AllergyIn patientImmunoassaybusiness.industryViral VaccineCancerViral VaccinesImmunotherapymedicine.diseaseVaccinationInfectious Diseasesmedicine.anatomical_structureVirus DiseasesPractice Guidelines as TopicImmunologyImmunotherapybusinessCancer Vaccines/immunology; Cancer Vaccines/therapeutic use; Humans; Immunoassay/standards; Immunotherapy; Monitoring Immunologic/standards; Neoplasms/therapy; Practice Guidelines as Topic/standards; T-Lymphocytes/immunology; Viral Vaccines/immunology; Viral Vaccines/therapeutic use; Virus Diseases/therapy

description

Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.

yearjournalcountryeditionlanguage
2009-10-01Immunity
https://doi.org/10.1016/j.immuni.2009.09.007